Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response.
- DOI
- 10.1002/acn3.70564
- Published
- 2026 Oct 26
- Container
- Annals of clinical and translational neurology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/acn3.70564,
title = {Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response.},
author = {Riolo G and Dosi C and Parravicini S and Zanin R and Cheli M and Grigoli EG and Canciello A and Andreetta F and Masson R and Bonanno S and Marcuzzo S and Maggi L},
year = {2026},
journal = {Annals of clinical and translational neurology},
doi = {10.1002/acn3.70564},
url = {https://doi.org/10.1002/acn3.70564}
}RIS
TY - JOUR TI - Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response. AU - Riolo G AU - Dosi C AU - Parravicini S AU - Zanin R AU - Cheli M AU - Grigoli EG AU - Canciello A AU - Andreetta F AU - Masson R AU - Bonanno S AU - Marcuzzo S AU - Maggi L PY - 2026 JO - Annals of clinical and translational neurology DO - 10.1002/acn3.70564 UR - https://doi.org/10.1002/acn3.70564 ER -
APA
G, R., C, D., S, P., R, Z., M, C., EG, G., A, C., F, A., R, M., S, B., S, M., & L, M. (2026). Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response.. Annals of clinical and translational neurology. https://doi.org/10.1002/acn3.70564
Source records
- pubmed · retrieved 2026-11-10T15:12:31.023Z